جستجوی مقالات مرتبط با کلیدواژه « stimulating » در نشریات گروه « پزشکی »

Spinal cord injury (SCI) is one of the worst kinds of traumatic injuries with remarkable social and economic effects on communities.
Methods & Materials/Patients: In this prospective randomized clinical trial, 122 patients with traumatic spinal cord injury were admitted to Poursina hospital within 48 h of injury to compare G-CSF and high-dose methylprednisolone as neuroprotective therapy.
In this study, 122 patients were studied out of which 62 patients were included in the granulociote colony-stimulating factor (G-CSF) group with a mean age of 40.4, and 60 patients in the methylprednisolone group with an average age of 40.10 years. 55 patients (45%) out of 122 patients were completely paralyzed (Grade AIS: A) and 67 (55%) were with incomplete spinal injury (Grade AIS: B, C, D). The average ASIA sensory scores in the two groups were similarly compared in the same time intervals, and p values were 0.7, 0.3, 0.2, and 0.1, respectively . They were not statistically significant.
According to the results, the G-CSF was shown to be beneficial in average ASIA motor and sensory scores in the two groups of male patients at six months of onset of G-CSF treatment (p value=0.04) and average ASIA motor scores improvement in the falls subgroup patients also differed significantly within six months of onset of G-CSF treatment (p value=0.03). A multicentre prospective randomized clinical trial to compare the placebo effect with G-CSF protocol's treatment, and also assessment of the cost benefits of the common medical treatment versus G-CSF are n eeded.

Spinal cord injury (SCI) is one of the worst kinds of traumatic injuries with remarkable social and economic effects on communities.
Methods & Materials/Patients: In this prospective randomized clinical trial, 122 patients with traumatic spinal cord injury were admitted to Poursina hospital within 48 h of injury to compare G-CSF and high-dose methylprednisolone as neuroprotective therapy.
In this study, 122 patients were studied out of which 62 patients were included in the granulociote colony-stimulating factor (G-CSF) group with a mean age of 40.4, and 60 patients in the methylprednisolone group with an average age of 40.10 years. 55 patients (45%) out of 122 patients were completely paralyzed (Grade AIS: A) and 67 (55%) were with incomplete spinal injury (Grade AIS: B, C, D). The average ASIA sensory scores in the two groups were similarly compared in the same time intervals, and p values were 0.7, 0.3, 0.2, and 0.1, respectively . They were not statistically significant.
According to the results, the G-CSF was shown to be beneficial in average ASIA motor and sensory scores in the two groups of male patients at six months of onset of G-CSF treatment (p value=0.04) and average ASIA motor scores improvement in the falls subgroup patients also differed significantly within six months of onset of G-CSF treatment (p value=0.03). A multicentre prospective randomized clinical trial to compare the placebo effect with G-CSF protocol's treatment, and also assessment of the cost benefits of the common medical treatment versus G-CSF are n eeded.

Hashimoto's encephalopathy (HE) is a rare condition characterized by atypical psychiatric and heterogeneous neurological manifestations such as acute cerebral ischemia, seizure, tremors, myoclonus, psychosis, depression, cognitive disorders, and fluctuating loss of consciousness. Here, a case of 28 year-old man was reported who referred to the emergency department (ED) with different acute neurologic disorders and final diagnose of HE.